Ensign Group (ENSG) Updates Bylaws, Is It Still 14% Below Fair Value?

Ensign Group (ENSG) recently approved amended and restated bylaws that refine how stockholder meetings, director nominations, and proposal deadlines are handled, giving investors fresh context for evaluating governance alongside recent legal and short seller developments.

At a share price of US$170.79, Ensign Group has seen modest short term pressure, with the 30 day share price return down 4.4% and the 1 year total shareholder return down 1.7%. Longer term holders have seen materially stronger total returns over three and five years, suggesting momentum has cooled as investors weigh recent short seller allegations, legal investigations and the updated bylaws.

Compare how Ensign Group stacks up against other healthcare operators facing governance and legal scrutiny by scanning a curated set of 82 resilient stocks with low risk scores that may offer steadier risk profiles.

The recent pullback at Ensign Group could hint at deeper worries about care quality and governance, or it could simply reflect cooler sentiment after strong multi year returns. How does that translate into what investors are currently paying for the business?

Price-to-Earnings of 26.1x: Is it justified for Ensign Group?

On a P/E of 26.1x, Ensign Group trades at a higher earnings multiple than both its peer group average of 15.2x and the broader US Healthcare industry average of 25.3x, even though the stock is currently 14.2% below one estimate of fair value from the SWS DCF model.

The P/E ratio compares what investors are willing to pay today for each dollar of current earnings. For a healthcare operator like Ensign Group, it often reflects expectations around the durability of earnings, the quality of care delivery and the perceived resilience of cash flows through industry and regulatory cycles.

Here, the market is paying a premium P/E versus peers even though Ensign Group has a 1 year total shareholder return that has lagged both the US market and the US Healthcare sector. Earnings have grown 14.2% per year over the past 5 years and are forecast to continue growing, although not at very high rates compared with some faster growing stocks. The SWS fair P/E estimate of 26.3x sits very close to the current 26.1x. This suggests the current multiple is in line with the level that quantitative fair value work indicates the market could gravitate toward over time.

Relative to the industry, that small gap between Ensign Group's current P/E and the estimated fair P/E is meaningful. The stock is more expensive than the average healthcare operator on headline multiple, yet sits almost exactly on top of the fair ratio level implied by the SWS regression model. That combination points to a company where investors may already be pricing in its earnings quality and governance profile, rather than leaving obvious multiple based mispricing on the table.

Explore the SWS fair ratio for Ensign Group.

Result: Price-to-Earnings of 26.1x (ABOUT RIGHT)

However, the short seller allegations and ongoing legal investigations around Ensign Group, along with fresh scrutiny of its governance, could quickly change how investors view that current P/E premium.

Find out about the key risks to this Ensign Group narrative.

Another view on Ensign Group using the SWS DCF model

The first check on Ensign Group focused on its P/E ratio, which looked roughly in line with the fair ratio. The SWS DCF model points in a different direction. At a share price of $170.79 and an estimated future cash flow value of $198.98, the stock screens as about 14.2% undervalued. That raises a simple question for investors: should more weight go to the earnings multiple premium or to the cash flow signal?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Ensign Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of caution and potential around Ensign Group feels familiar, take it as a prompt to review the data directly and consider the 4 key rewards.

Looking for more investment ideas beyond Ensign Group?

If Ensign Group has sharpened your focus, do not stop here. Broaden your watchlist with fresh company ideas so you are not missing other potential opportunities.

• Target potential value opportunities by reviewing a curated 47 high quality undervalued stocks that may trade below what their fundamentals suggest.
• Strengthen your income stream by scanning a hand picked set of 11 dividend fortresses that offer higher yields with robust profiles.
• Prioritise financial resilience by filtering for a list of solid balance sheet and fundamentals (52 results) that can better withstand shocks and still support growth.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com